Raymond James Trust N.A. Has $321,000 Stake in Organon & Co. (NYSE:OGN)

Raymond James Trust N.A. lowered its stake in Organon & Co. (NYSE:OGN) by 5.0% in the second quarter, Holdings Channel reports. The fund owned 15,495 shares of the company’s stock after selling 812 shares during the quarter. Raymond James Trust N.A.’s holdings in Organon & Co. were worth $321,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in OGN. Versant Capital Management Inc lifted its stake in Organon & Co. by 200.2% in the 2nd quarter. Versant Capital Management Inc now owns 1,207 shares of the company’s stock valued at $25,000 after purchasing an additional 805 shares during the last quarter. Gladius Capital Management LP increased its holdings in shares of Organon & Co. by 65.1% during the fourth quarter. Gladius Capital Management LP now owns 2,176 shares of the company’s stock worth $31,000 after buying an additional 858 shares in the last quarter. Fidelis Capital Partners LLC bought a new position in shares of Organon & Co. in the 1st quarter valued at $43,000. Tompkins Financial Corp grew its holdings in Organon & Co. by 450.7% during the 1st quarter. Tompkins Financial Corp now owns 2,412 shares of the company’s stock worth $45,000 after acquiring an additional 1,974 shares during the last quarter. Finally, GAMMA Investing LLC acquired a new position in Organon & Co. in the 4th quarter valued at approximately $38,000. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Organon & Co. Stock Performance

Shares of OGN stock opened at $22.41 on Wednesday. The stock has a market capitalization of $5.76 billion, a PE ratio of 5.48, a PEG ratio of 0.90 and a beta of 0.85. The business’s 50 day simple moving average is $20.82 and its 200 day simple moving average is $19.72. The company has a debt-to-equity ratio of 60.05, a current ratio of 1.64 and a quick ratio of 1.17. Organon & Co. has a one year low of $10.84 and a one year high of $23.10.

Organon & Co. (NYSE:OGN) last issued its earnings results on Tuesday, August 6th. The company reported $1.12 EPS for the quarter, beating the consensus estimate of $1.08 by $0.04. Organon & Co. had a negative return on equity of 840.29% and a net margin of 15.76%. The company had revenue of $1.61 billion during the quarter, compared to the consensus estimate of $1.61 billion. During the same period last year, the business posted $1.31 EPS. The firm’s revenue for the quarter was down .1% compared to the same quarter last year. As a group, research analysts forecast that Organon & Co. will post 4.14 earnings per share for the current year.

Organon & Co. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 12th. Stockholders of record on Friday, August 16th will be issued a dividend of $0.28 per share. The ex-dividend date is Friday, August 16th. This represents a $1.12 annualized dividend and a dividend yield of 5.00%. Organon & Co.’s dividend payout ratio is 27.38%.

Analyst Ratings Changes

Separately, The Goldman Sachs Group boosted their price objective on shares of Organon & Co. from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.